Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PMV Pharmaceuticals, Inc. Director's Dealing 2022

Feb 8, 2022

34350_dirs_2022-02-08_de53b8ab-30f6-4294-b86d-fc61682a31af.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2021-12-30

Reporting Person: Kung Winston (COO, CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-30 Common Stock G 2725 $0.00 Disposed 6600 Direct

Footnotes

F1: The reported shares were acquired under the Issuer's stock purchase plan on May 20, 2021.